Search

Bio Roundup: Prices on TV, Novartis Hearts Radio, Warp Drive's End

BIO ROUNDUP: PRICES ON TV, NOVARTIS HEARTS RADIO, WARP DRIVE'S END

Two new battlegrounds emerged this week in the nation's ongoing drug pricing debate. The first involved television: The federal government...

 
 
 
Nobel Medicine Prize Honors Cancer Immunotherapy Pioneers Allison & Honjo

NOBEL MEDICINE PRIZE HONORS CANCER IMMUNOTHERAPY PIONEERS ALLISON & HONJO

[ Updated 11:45 am ET Oct. 1 with comments from press conference ] Harnessing the immune system to fight cancer has transformed the...

 
 
 
Bio Roundup: Alnylam's Moment, Read on Rebates, Skinny Plans & More

BIO ROUNDUP: ALNYLAM'S MOMENT, READ ON REBATES, SKINNY PLANS & MORE

Millions of people might be on vacation as we hit the dog days, but drug makers and politicians aren't taking a break from the gamesmanship...

ASCO18: MIXED REACTION TO NEKTAR'S ‘CONFUSING' NKTR-214 TRIAL

Nektar Therapeutics' much-anticipated data from a study pairing its immuno-oncology prospect NKTR-214 with Bristol-Myers Squibb's checkpoint...

 
 
 
Bio Roundup: CMS Backs Cancer Tests, Right to Try Passes, AbbVie Sinks

BIO ROUNDUP: CMS BACKS CANCER TESTS, RIGHT TO TRY PASSES, ABBVIE SINKS

We'll start this week's roundup with several stories from Washington, D.C. that could have a lasting effect on public health. The FDA...

 
 
 

BRISTOL-MYERS' LUNG CANCER OPDIVO-YERVOY COMBO WOWS IN PHASE III STUDY

Additionally, based on an interim analysis for overall survival , the Data Monitoring Committee recommended that the study continue

HIV breakthrough as cancer drug does wonders for patient

HIV BREAKTHROUGH AS CANCER DRUG DOES WONDERS FOR PATIENT

A 51-year old French man given nivolumab - sold as Opdivo - saw a 'drastic and persistent decrease' in the reservoirs of cells where...

 
 
 

INNATE TANKED AS DRUG COMBINED WITH BRISTOL-MYERS' OPDIVO FLOPPED IN STUDY

While lirilumab was shown to be well-tolerated, it did not provide clear evidence of benefit to patients or an obvious development...

Roche Gains Ground on Rivals With Drug Combo's Success in Lung Cancer

ROCHE GAINS GROUND ON RIVALS WITH DRUG COMBO'S SUCCESS IN LUNG CANCER

Roche/Genentech reported this morning that its cancer immunotherapy drug, atezolizumab , has succeeded in a clinical study that could...

 
 
 
 
 
 
 
 
 
 
 
 

BRISTOL-MYERS SQUIBB RELEASE: PHASE III STUDY EVALUATING THE SAFETY AND EFFICACY OF ADJUVANT OPDIVO IN RESECTED HIGH-RISK MELANOMA PATIENTS MEETS PRIMARY ENDPOINT

Life Sciences Jobs ...

Bristol-Myers beat on earnings thanks to sales of its drugs that use the immune system to treat cancer

BRISTOL-MYERS BEAT ON EARNINGS THANKS TO SALES OF ITS DRUGS THAT USE THE IMMUNE SYSTEM TO TREAT CANCER

Thomson Reuters NEW YORK - Bristol-Myers Squibb Co on Thursday posted better-than-expected first-quarter earnings, helped by growth...